rs104894138 — CYP17A1 Arg96Trp (R96W)

The Enzyme That Makes Cortisol and Sex Steroids — Broken at the Switch

CYP17A1 encodes cytochrome P450 17α-hydroxylase/17,20-lyase, an enzyme that sits at a critical junction in human steroid biosynthesis. It performs two consecutive chemical reactions: first converting pregnenolone to 17α-hydroxypregnenolone (the 17-hydroxylase step), then cleaving that intermediate to yield DHEA and other 17-ketosteroids¹¹ 17-ketosteroids
17-ketosteroids are precursors to testosterone, estradiol, and other sex steroids; without them, the gonads and adrenals cannot make sex hormones (the 17,20-lyase step). Both activities reside in the same enzyme active site, and the Arg96 residue sits in the substrate-binding region responsible for positioning steroid molecules for catalysis.

The Arg96Trp variant — a single nucleotide change on chromosome 10 — replaces arginine with tryptophan at position 96, disrupting the substrate-binding pocket and almost completely abolishing both enzymatic activities²² almost completely abolishing both enzymatic activities
Laflamme et al. expressed the R96W mutant in COS-1 cells and found near-total loss of both 17α-hydroxylase and 17,20-lyase function compared to wild-type. This is a rare autosomal recessive variant: homozygotes develop the full clinical syndrome of 17α-hydroxylase/17,20-lyase deficiency (17-OHD), while heterozygous carriers are generally unaffected but carry the variant for transmission to offspring.

The Mechanism

When CYP17A1 is non-functional, steroid precursors are shunted entirely into the mineralocorticoid pathway. The adrenal glands overproduce 11-deoxycorticosterone (DOC) and corticosterone³³ 11-deoxycorticosterone (DOC) and corticosterone
DOC and corticosterone are potent mineralocorticoids that act on the kidney to retain sodium and water, raising blood pressure and suppressing renin; they are normally minor products but become the dominant adrenal steroids when CYP17A1 fails. The result is volume-dependent hypertension, hypokalemia (low potassium), and suppressed renin — a distinctive biochemical fingerprint. Simultaneously, cortisol cannot be made, so ACTH rises chronically (ACTH is the pituitary hormone that drives adrenal function), further amplifying DOC and corticosterone overproduction.

Sex steroid synthesis collapses entirely: no DHEA, no androstenedione, no testosterone, no estradiol from either gonads or adrenals. In 46,XY individuals, the testes cannot produce testosterone during fetal development, producing female external genitalia (complete sex reversal) and undescended testes. In 46,XX individuals, the ovaries cannot produce estrogen, causing primary amenorrhea and absent pubertal development, though the uterus is present and fertility may be possible with treatment.

The Evidence

The R96W variant was first characterized in 1996 by Laflamme et al.⁴⁴ 1996 by Laflamme et al.
JCEM 1996; 81(1):264-268 — two homozygous French-Canadian 46,XY siblings with combined 17-OHD; site-directed mutagenesis in COS-1 cells showed near-complete abolition of both enzymatic activities. Subsequent case reports have confirmed the same clinical syndrome across populations. A 2010 Brazilian case⁵⁵ 2010 Brazilian case
Costenaro et al., Arq Bras Endocrinol Metabol 2010; 54(8):744-748 — a 16-year-old 46,XY phenotypic female with primary amenorrhea, hypertension, and hypokalemia documented the classic presentation: raised as female, never menstruated, found to have a 46,XY karyotype with no sex steroid production. ClinVar (VCV000001785) classifies R96W as pathogenic/likely pathogenic based on 11 out of 12 submissions from major genetics laboratories, supported by functional evidence of ~10–30% residual enzyme activity.

Codon 96 appears structurally critical: the R96Q variant at the same position⁶⁶ R96Q variant at the same position
Brooke et al., JCEM 2006; 91(6):2428-2431 — R96Q identified independently, causes complete P450c17 inactivity; demonstrates that any substitution at Arg96 disrupts the substrate-binding region causes an identical clinical syndrome, reinforcing that Arg96 is essential for positioning substrates in the active site.

ClinVar review status: "criteria provided, multiple submitters, no conflicts" — the highest level of confidence for a rare variant short of expert panel review.

Practical Actions

For homozygous individuals (full 17-OHD), treatment requires lifelong glucocorticoid replacement to suppress ACTH, normalize mineralocorticoid excess, and control hypertension. Sex steroid replacement is also needed: estrogen (with progesterone if a uterus is present) for 46,XX individuals and for 46,XY individuals raised as female; testosterone replacement if the individual identifies as male. Blood pressure should be monitored at every visit, as it may normalize with glucocorticoid therapy alone but sometimes requires additional antihypertensives.

Fertility is possible for 46,XX women with 17-OHD. A 2025 case series⁷⁷ 2025 case series
Chai et al., J Assist Reprod Genet 2025; 42(7) — four Chinese women with 17-OHD completed eight IVF frozen embryo transfer cycles; glucocorticoid pretreatment enabled adequate endometrial preparation; three live births resulted demonstrated successful pregnancies through IVF with glucocorticoid-supplemented frozen embryo transfer protocols. Pregnancy in 17-OHD requires specialist obstetric care with careful blood pressure management.

For heterozygous carriers, the condition is autosomal recessive: carriers have one functional gene copy and do not develop the clinical syndrome. The reproductive significance is that two carrier parents have a 25% chance of an affected child per pregnancy. Reproductive genetic counseling and preimplantation genetic testing (PGT-M) are available options.

Interactions

17-OHD caused by R96W belongs to the same clinical syndrome as 17-OHD caused by other CYP17A1 mutations. The POR gene (encoding P450 oxidoreductase, the electron donor for CYP17A1) and CYB5A gene (encoding cytochrome b5, an allosteric activator of the 17,20-lyase step) can cause overlapping phenotypes when mutated. These represent different genetic causes of the same enzymatic pathway dysfunction and are not compound interactions with rs104894138.

The drug abiraterone acetate pharmacologically replicates CYP17A1 deficiency by inhibiting the same enzyme — its clinical use in prostate cancer produces the same mineralocorticoid excess profile seen in genetic 17-OHD, requiring concurrent prednisone to suppress ACTH-driven DOC overproduction.